Objective: To identify risk factors for central nervous system infection (CNSI) following glioma resection and develop a predictive model. Methods: Retrospective analysis of 435 glioma resection cases was conducted to assess CNSI risk factors. A nomogram predictive model was constructed and validated internally and externally. CSF characteristics and antibiotic use in CNSI patients were summarized and the impact of CNSI on long-term prognosis was evaluated. Results: CNSI incidence was 14.9%. Independent risk factors included ventricular opening, postoperative systemic infection, maximum diameter ≥ 5 cm, and preoperative peripheral blood monocyte percentage ≥ 10%. The predictive model showed good performance (C statistic = 0.797, AUC = 0.731). CNSI patients had elevated CSF protein and leukocytes, with meropenem and vancomycin as primary antibiotics. CNSI had no significant impact on long-term prognosis. Conclusions: Key risk factors for CNSI were identified, and an effective predictive model was established, providing important references for clinical decision-making and CNSI management.
This review explores the nuanced decision-making surrounding postoperative radiotherapy for diffuse low-grade glioma patients, emphasizing the need for individualized treatment to balance the benefits of tumor control with the risks of side effects. Radiotherapy is a cornerstone of diffuse low-grade glioma treatment, offering significant improvements in progression-free survival, but its potential for quality of life necessitates careful consideration of individual patient factors. The review delves into the radiotherapy timing, revealing that while early radiotherapy enhances progression-free survival, it does not significantly impact overall survival and may lead to severe and prolonged decline in long-term quality of life. Conversely, delayed radiotherapy may mitigate these side effects. The review advocates for a patient-centered approach, emphasizing the importance of weighing individual risks and benefits, and highlights the potential of artificial intelligence in predicting quality of life and the need to revisit previous research findings in light of the 2021 WHO (World Health Organization) classification update, underscoring the evolving nature of low-grade glioma treatment and the ongoing quest for optimal therapeutic strategies.